INTRODUCTION
============

Pregnancy induces physiological, hormonal, and physical changes that may cause hypertensive, hemorrhagic, hematological, and liver complications. Less than 1% of women require admission to an intensive care unit (ICU) during pregnancy and the peripartum period, which is associated with increased maternal and fetal mortality.^([@r01])^ Preeclampsia, HELLP (hemolysis, elevated liver enzymes, and low-platelet count) syndrome, and acute fatty liver of pregnancy (AFLP) are the main causes of thrombotic microangiopathy^([@r02])^ and severe liver dysfunction during pregnancy and most likely represent several manifestations of the same pathological continuum.^([@r03])^

The present article describes an uncommon case of acute subdural hematoma and intracerebral hemorrhage occurring as fatal complications of severe thrombotic microangiopathy during pregnancy.

CASE REPORT
===========

The patient was a black female, aged 36 years old, with a past history of an abortion two years prior. As an asthmatic, she used inhaled bronchodilators and was admitted to the hospital at a gestational age of 35 weeks due to nausea, vomiting, jaundice, abdominal pain, and cessation of fetal movements starting two days prior; fetal death was diagnosed. The patient\'s blood pressure was normal (maximum of 130/80 mmHg before delivery), and she presented without fever but developed tachycardia during the first hours of hospitalization. A cesarean section with general anesthesia was performed on day two of hospitalization, and the patient was immediately transferred to the ICU.

Upon admission to the ICU, crystalloid fluid resuscitation was performed, and the patient\'s vital signs, level of consciousness, lochia, and surgical wound were closely monitored. The laboratory tests ([Table 1](#t01){ref-type="table"}) indicated anemia with a hemoglobin concentration of 10.6 g/dL; fragmented red blood cells; a platelet count of 232,000/mm^3^, leukocytosis with a left shift (total white cell count, 24,800/mm^3^; and band cell count 2,728/mm^3^); aspartate transaminase (AST), 150 U/L; alanine transaminase (ALT), 152 U/L; total bilirubin, 6.31 mg/dL; direct bilirubin, 4.29 mg/dL; lactic dehydrogenase (LDH), 1,249 U/L; alkaline phosphatase (ALP), 314 U/L; kidney failure (creatinine, 2.88 mg/dL; urea, 94 mg/dL); increased partial thromboplastin time (51.5 seconds), normal initial prothrombin time, negative D-dimer non-coagulant fibrinogen (more than ten times the upper limit); significant proteinuria with a proteinuria/creatinuria ratio of 0.7; uric acid, 7 mg/dL; pH 7.30; pCO~2~, 36 mmHg; HCO~3~, 18.3 mmol/L; Base Excess, -7.4 mmol/L; and arterial plasma lactic acid, 3.7 mmol/L. The patient exhibited frequent hypoglycemic episodes from day two to day six of hospitalization. Based on the clinical and laboratory data at the time of ICU admission, the following diagnostic possibilities were suggested: postpartum preeclampsia, AFLP, and/or HELLP syndrome.

###### 

Laboratory tests performed during hospitalization

  **Test/reference value**                       **Day 1**                                     **Day 3**   **Day 5**   **Day 11**   **Day 17**   **Day 22**
  ---------------------------------------------- --------------------------------------------- ----------- ----------- ------------ ------------ ------------
  Hemoglobin (11.1-16.1 g/dL)                    10.6                                          8.5         4.6         10.0         5.8          7.6
  Hematocrit (35-47%)                            31.4                                          24.8        13.6        30.6         16.8         22.3
  Total white blood cells (3,600-11,000/mm^3^)   24,800                                        33,900      19,600      22,200       20,600       9,400
  Platelets (150,000-450,000/mm^3^)              232                                           176         183         59           207          159
  Lactic dehydrogenase (207-414 U/L)             1,249                                         2,357       2,101       1,220        1,262        1,143
  Aspartate transaminase (5-46 U/L)              150                                           141         135         \-\--        \-\--        118
  Alanine transaminase (3-50 U/L)                152                                           92          74          \-\--        \-\--        192
  Total/direct bilirubin (up to 1.2/0.4 mg/dL)   6.31/4.29                                     6.61/4.47   11.85/7.2   8.81/5.61    6.27/4.31    4.43/2.6
  Alkaline phosphatase (50-136 U/L)              314                                           \-\--       \-\--       80           \-\--        \-\--
  Prothrombin time (PT)                          1.00                                          1.79        1.22        0.95         1.12         0.9
  Partial thromboplastin time (16-34 s)          51.5                                          76.2        54.2        27.1         29.4         29.5
  Albumin (3.5-5.5 g/dL)                         \-\--                                         \-\--       2.5         2.4          \-\--        \-\--
  Creatinine (0.6-1.3 mg/dL)                     2.88                                          3.67        2.79        1.76         2.13         2.01
  Urea (10-45 mg/dL)                             94                                            137         177         202          143          120
  Sodium (135-147 mEq/L)                         144                                           132         140         168          138          142
  Calcium (8.8-11 mg/dL)                         10.89                                         7.6         8.2         9.6          8.2          \-\--
  Lactic acid (0.5-1.6 mmol/L)                   3.7                                           1.6         \-\--       1.7          \-\--        \-\--
  Uric acid (1.5-6.0 mg/dL)                      7.0                                           7.9         9.7         \-\--        \-\--        \-\--
  Fibrinogen (150-350 mg/dL)                     Non-coagulating: \>10 times the upper limit   \-\--       178         \-\--        \-\--        \-\--
  D-dimers (15-147 ng/mL)                        4.4                                           \-\--       \-\--       \-\--        \-\--        \-\--

\-\-\-- not performed on that day.

Intermittent peaks of systemic arterial hypertension started on day three, reached a maximum of 178/86 mm Hg, and lasted 18 days. To assess the liver and kidneys, total abdomen computed tomography (CT) was performed on day six, which revealed a hematoma at the rectus abdominis muscle (mostly on its right side), the lower portion of which measured approximately 4.5 cm (an usual finding after cesarean sections). No other significant changes were found. The patient exhibited oligoanuria starting on day 10, which was accompanied by signs of anasarca and necessitated hemodialysis. A large left pleural effusion ([Figure 1](#f01){ref-type="fig"}) with transudate characteristics developed on day 15 after delivery and was accompanied by acute respiratory failure. Left chest drainage was performed, and mechanical ventilation was initiated following intubation.

![Chest computed tomography scan showing a large left pleural effusion and a left collapsed lung.](rbti-25-02-0175-g01){#f01}

Until pre-intubation sedation, the patient\'s level of consciousness was normal, with no abnormal findings on the neurological examination, a score of 15 on the Glasgow coma scale, equal-size and light-reactive pupils, and no focal signs. Two days later, while still sedated, intubated, and under unweanable mechanical ventilation, the patient exhibited a sudden hypertensive crisis with vomiting and the appearance of mydriasis in the left eye. The hypertension was immediately treated, an antiemetic was administered, and the analgesic doses were increased. Cranial CT was performed ([Figure 2](#f02){ref-type="fig"}), which revealed the presence of an acute subdural hematoma and a parietal-occipital intracerebral hemorrhage on the left side. The patient was immediately subjected to emergency neurosurgical treatment.

![Cranial computed tomography scan showing an acute subdural hematoma with a midline shift and a subcortical hemorrhage in the left occipital lobe.](rbti-25-02-0175-g02){#f02}

The patient exhibited profuse bleeding with an onset at the beginning of surgery and lasting throughout the transoperative period, accompanied by hemodynamic instability that was difficult to manage despite fluid replacement, blood component transfusion, and the use of vasoactive drugs. Following two trepanations, the hypertensive hygroma and hematoma, which displayed both acute and chronic components, were drained. Notably, the original neurosurgical plan had been to perform a decompressive craniotomy and to treat the acute subdural hematoma; however, the anesthetist had to interrupt the procedure because of progressive and refractory hemodynamic deterioration despite aggressive management. Therefore, only the two trepanations were performed to drain the subdural collection.

Subsequently, the patient exhibited spontaneous bleeding at other sites, such as the mouth, nose, and vagina (although the coagulation tests had been normal up to that point), with persistence of hemolytic anemia and refractory shock. Four days after neurosurgery, the patient presented with bilateral mydriasis and nonreactive pupils. Sedation was discontinued, and her Glasgow score was 3. The maximal LDH level was 2,357 U/L, being 1,143 U/L at 20 days after delivery. The maximal total bilirubin concentration was 12.23 mg/dL. The maximal direct bilirubin was 8.29 mg/dL, being 1.43 at 20 days after delivery, when the AST was 118 U/L, and the ALT was 192 U/L. The minimal hemoglobin concentration was 4.6 g/dL and occurred five days after delivery, whereas it had risen to 5.8 g/dL on the day neurological deterioration occurred. The minimal platelet count was 54,000/mm^3^, reaching and maintaining normal levels starting at day 15 after delivery. Leukocytosis with a left shift was found on most of the days, with a maximum of 29,700 white blood cells/mm^3^. The maximal creatinine concentration was 3.67 mg/dL, and that of urea was 202 mg/dL.

Serologic tests for hepatitis and the human immunodeficiency virus (HIV) were performed but were negative. Furthermore, the immunological tests for systemic lupus erythematosus and rheumatoid arthritis failed to detect any alteration. Plasmapheresis was not performed at any time because the hypothesis of AFLP predominated in the clinical diagnosis. Likewise, magnesium sulfate was not administered to prevent seizures because of the late diagnosis of postpartum preeclampsia. Nevertheless, the levels of magnesium were measured and found to be normal (2.1 to 2.4 mg/dL) throughout the hospitalization.

The diagnosis of brain death could not be established because the patient was absolutely unresponsive to stimuli and exhibited a complete absence of brain stem reflexes upon neurological examination, due to the refractory hemodynamic instability that had set in combined with the clinical and neurological deterioration despite the fluid resuscitation, use of vasopressors, and blood component transfusion. The patient died five days after surgery, which was 22 days after the delivery.

DISCUSSION
==========

Preeclampsia is characterized by hypertension, proteinuria, and edema. It affects approximately 5 to 7% of pregnant women, 65% of whom might progress to HELLP syndrome. For these reasons, preeclampsia remains a significant cause of maternal morbidity and mortality. Typically, preeclampsia occurs during the second or third trimester of pregnancy, but occasionally, the disease has been detected before gestational week 20. Its consequences include hypertensive crises, kidney failure, liver rupture, neurological complications such as seizures and stroke, and increased perinatal morbidity and mortality. The pathogenesis of preeclampsia is believed to be associated with placental ischemia, endothelial dysfunction, and cytotoxic and genetic factors. Severe preeclampsia is defined by systolic arterial pressure levels that are persistently \>160 mmHg or diastolic arterial pressure \>110 mmHg, massive proteinuria (4+ in a dipstick, or \>2.0 g/24 hours), or the presence of clinical (epigastric pain, nausea, and vomiting) and laboratory (platelet count \<50,000/mm^3^, creatine kinase \>200 U/L, LDH \>1,400 U/L, AST \>150 U/L, ALT \>100 U/l, uric acid \>7.8 mg/dL, and serum creatinine \>1.2 mg/dL) manifestations.^([@r04])^

AFLP is a rare and potentially fatal disorder that might occur at the third trimester of pregnancy, involves microvesicular fatty infiltration of hepatocytes, and has a mortality rate of up to 70%. In most studies, the estimated incidence is 1:10,000-15,000 pregnancies, with mortality of 10 to 20%. AFLP occurs more often in multiple pregnancies, male fetuses, and nulliparous women. AFLP is associated with inherited defects of the mitochondrial fatty acid beta-oxidation, as well as with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD), including the G 1529C mutation.^([@r03])^ The earliest symptoms usually include nausea, vomiting, abdominal (mainly epigastric) pain, lack of appetite, jaundice, fever, headache, and itch. Approximately one third of patients exhibit signs of preeclampsia at the onset or during the progression of the disease. The diagnosis is usually clinical and is based on the laboratory and compatible imaging findings, including increased values for AST, ALT, bilirubin, uric acid, creatinine, leukocytes, clotting, and electrolytes, as well as blood glucose (hypoglycemia) disorders and lactic acidosis. The present case exhibited clinical and laboratory features compatible with AFLP, HELLP syndrome, and severe preeclampsia. As the clinical manifestations of AFLP prevailed at the disease onset, treatment was directed against that condition and was thus limited to intensive clinical support care, which includes immediate delivery following maternal stabilization because there is no specific treatment for this disease.

HELLP syndrome is a severe form of preeclampsia that usually affects 4 to 12% of women with preeclampsia. This syndrome is associated with microthrombi, thrombocytopenia, and clotting disorders and has a poor prognosis. HELLP syndrome may appear from the second trimester of pregnancy up to several days after delivery; in one third of cases, the syndrome appears after childbirth.^([@r03])^ HELLP syndrome is associated with vasoconstriction, increased vascular tonus, platelet aggregation, and an altered thromboxane/prostacyclin ratio. HELLP syndrome is partially caused by activation of the complement and consequent coagulation cascade, resulting in endothelial and microvascular injury in multiple organs, microangiopathic hemolytic anemia, periportal and liver necrosis with increased liver enzymes, and thrombocytopenia. Both AFLP and HELLP syndrome affect the liver, but HELLP syndrome is more common (1:5,000 births). AFLP tends to occur later in the pregnancy and causes reduced liver synthetic function, resulting in hypoglycemia, increased ammonia levels, and clotting disorders. Disseminated intravascular coagulation is common in both conditions; however, the AST and ALT disorders and the increased LDH are more typical of HELLP syndrome, whereas the bilirubin increase is greater in AFLP ([Table 2](#t02){ref-type="table"}).^([@r05])^

###### 

Clinical features of the liver diseases during pregnancy

  **Disease**                      **Trimester**                  **Aminotransferases (U/L)**                           **Total bilirubin (mg/dL)**   **Others laboratory tests**                                      **Differential diagnosis**                                                                                                                                               **Prognosis**
  -------------------------------- ------------------------------ ----------------------------------------------------- ----------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------
  Hyperemesis gravidarum           1^st^                          \<200 (ALT \>AST) up to 1,000                         \<4                                                                                            Gastroenteritis, cholecystitis, hepatitis, intestinal obstruction, peptic ulcer, pancreatitis, appendicitis, diabetic ketoacidosis, hyperparathyroidism, drug toxicity   Rare maternal and fetal mortality; might relapse
  HELLP syndrome                   2^nd^, 3^rd^, and postpartum   \<500 (mean 250) except in case of liver infarction   ↑ (mean 1.5)                  Platelets \<100,000 LDH \>600                                    Acute fatty liver of pregnancy, gastroenteritis, hepatitis, pyelonephritis, appendicitis, gall stones, idiopathic thrombocytopenic purpura, hemolytic uremic syndrome    Low maternal mortality; frequent maternal complication; fetal death up to 35%; relapse in 3-27%
  Intrahepatic cholestasis         3^rd^ and postpartum           Usually \<500 occasionally \>1,000                    \<6                           ALP four times the normal value                                  Gall stones, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, drug hepatotoxicity                                                             Rare maternal mortality; fetal death in 1-2%; associated with prematurity and stillbirth; relapse in 60-70%
  Acute fatty liver of pregnancy   3^rd^ and postpartum           \<500 up to a 1,000                                   ↑                             White blood cells ↑, PT ↑, platelets ↓, glucose ↓, uric acid ↑   HELLP, drug toxicity, fulminant liver failure                                                                                                                            Maternal mortality \<3%; fetal death from 35-45%; rare relapse

Adapted from: Sibai BM. HELLP syndrome. Up to Date. 2013 \[cited January 29, 2013\]. Available at <http://www.uptodate.com/contents/hellp-syndrome>.^([@r05])^ ALT - alanine-aminotransferase; AST - aspartate-aminotransferase; LDH - lactic dehydrogenase; ALP - alkaline phosphatase; PT - prothrombin time.

The risk of stroke during pregnancy is low; however, when stroke does occur, the morbidity and mortality of its complications are high. Recent studies reported an association between stroke during pregnancy and a history of migraine, gestational diabetes, preeclampsia, and eclampsia,^([@r06])^ which most likely indicates physiopathological mechanisms other than those associated with stroke that is unrelated with pregnancy.

The hematological disorders occurring in these conditions increase the risk of spontaneous postpartum bleeding, with intracranial hemorrhage as the main cause of death in women with preeclampsia.^([@r07])^ In addition, hypertension acts as an independent cause of stroke because the loss of the self-regulatory mechanisms of the brain blood flow leads to vasodilation and brain edema, particularly in the case of individuals without chronic hypertension. Brain ischemia and hemorrhage are almost always accompanied by a blood pressure increase of at least 10% due to alteration of the self-regulatory mechanisms induced by vasoactive substance release at the injury site.^([@r08])^

Cases of spontaneous peripartum acute subdural hematoma and intracerebral hemorrhage have been reported in the literature, but in association with the HELLP syndrome^([@r09])^ or with thrombocytopenia caused by idiopathic thrombocytopenic purpura.^([@r10])^ No case of spontaneous acute subdural hematoma associated with AFLP could be found in the literature.

The present patient exhibited an unfavorable progression partially due to the late diagnosis of preeclampsia. In this regard, it is noteworthy that the hypertension peaks first appeared a few days after the delivery and that the patient had undergone regular prenatal care. In addition, the late diagnosis of fetal death contributed to the fatal outcome. Indeed, the fetal movements had ceased two days prior to hospital admission, and the patient had sought medical care from the very onset of the symptoms, thus indicating a delay in the pre-hospital and emergency care. Retrospectively, one might wonder whether plasmapheresis might have modified the clinical progression, as hemolysis remained throughout the disease course. Plasmapheresis is indicated for patients with persistent HELLP syndrome,^([@r11])^ but there are no reports on the use of this modality for AFLP.

CONCLUSION
==========

Preeclampsia, HELLP syndrome, and acute fatty liver of pregnancy are pathological disorders that may overlap with one another and be associated with potentially fatal complications, such as intracranial hemorrhage, as in the case reported herein. Early detection and diagnosis are crucial to ensure appropriate management and treatment success.
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